Clinical Trial Update: An Observational Study of Maviret (Glecaprevir/Pibrentasvir) for Korean Chronic Hepatitis C Genotypes 1 to 6 Patients According to the Standard for Re-examination of New Drugs

View source ↗

Summary

An observational real-world study of Maviret (glecaprevir/pibrentasvir) in Korean patients with chronic hepatitis C genotypes 1–6 has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Maviret (glecaprevir/pibrentasvir)

Snippet

Sponsor: AbbVie | Conditions: Hepatitis C | Status: COMPLETED